Overall rank by patents
#34,644
of 49,997 tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Cancer Therapeutics CRC Pty Ltd
USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Cancer ranks #34,644 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.
- #34,644
- of 49,997 US assignees by volume
- 26th percentile
- by Innovation Score (28.2/100)
- 24.9
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R34644 · Foreign Corporation #34,644 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 7 grants
- MID-PACK #34,644/49,997
- PHOTO-FINISH Callsign
- CPC-NARROW A61P · 3 areas
- INNOV-THIN 28.2/100
- CLAIMS-DENSE 24.9 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Callsign Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Innovation-score neighbourhood around Cancer
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Cancer Therapeutics… · this assignee 28
Cancer Therapeutics… · this assignee
28 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Cancer's Innovation Score is 28.2/100 (26th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Where Cancer's grants concentrate
Cancer Therapeutics CRC Pty Ltd is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2018. By volume, Cancer sits between Callsign Inc. and Capitol AI, Inc..
Who files at Cancer's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Callsign
Callsign Inc.
7 patents
- Camcon Auto
Camcon Auto Limited
7 patents
- Can Do Logistics
Can Do Logistics LLC
7 patents
- Canada Pooch
Canada Pooch Ltd.
7 patents
- Candi Controls
Candi Controls, Inc.
7 patents
- Cantex Internatio…
Cantex International, Inc.
7 patents
- Cap Barbell
Cap Barbell, Inc.
7 patents
- Capitol AI
Capitol AI, Inc.
7 patents
- Cancer Therapeuti… ◀
Cancer Therapeutics CRC Pty Ltd
7 patents
What this shows Cancer holds 7 patents at rank #34,770, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Cancer
By rank, the assignees closest to #34,770 in granted patent volume.
- Callsign Inc. #34,766 · 7 patents
- Camcon Auto Limited #34,767 · 7 patents
- Can Do Logistics LLC #34,768 · 7 patents
- Canada Pooch Ltd. #34,769 · 7 patents
- Candi Controls, Inc. #34,771 · 7 patents
- Cantex International, Inc. #34,772 · 7 patents
- Cap Barbell, Inc. #34,773 · 7 patents
- Capitol AI, Inc. #34,774 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Cancer's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Cancer's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
28 26th percentile higher than 26% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 42.9% |
| 2016 | 3 | 42.9% |
| 2018 | 1 | 14.3% |
Which technologies does Cancer Therapeutics CRC Pty Ltd patent most?
Top 3 of 3 technology areas
What to do with this data
Cancer Therapeutics CRC Pty Ltd's patent record in context - here's where to go next.
- Cancer Therapeutics CRC Pty Ltd's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #34,644 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Cancer Therapeutics CRC Pty Ltd against Callsign Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 28.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.